These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33055536)

  • 1. Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
    Ziemer CM; Miedema J; Smith CJ; Liu Z; Thomas NE; Googe PB
    Am J Dermatopathol; 2021 Apr; 43(4):318-320. PubMed ID: 33055536
    [No Abstract]   [Full Text] [Related]  

  • 2. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
    Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
    Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
    [No Abstract]   [Full Text] [Related]  

  • 3. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
    Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
    Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab induced toxic epidermal necrolysis.
    Kumar R; Bhandari S
    Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
    [No Abstract]   [Full Text] [Related]  

  • 5. Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy.
    Miyagawa F; Nakajima A; Ohyama SI; Aoki Y; Nishikawa M; Nakamura Y; Hashimoto T; Asada H
    Acta Derm Venereol; 2019 Jun; 99(7):687-688. PubMed ID: 30938822
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxic epidermal necrolysis associated with pembrolizumab.
    Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
    Hwang A; Iskandar A; Dasanu CA
    J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
    Robinson S; Saleh J; Curry J; Mudaliar K
    Am J Dermatopathol; 2020 Apr; 42(4):292-296. PubMed ID: 31567395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor.
    Horii M; Kobayashi T; Maeda S; Takehara K; Matsushita T
    J Dermatol; 2019 Nov; 46(11):e434-e436. PubMed ID: 31342541
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
    Kian W; Zemel M; Elobra F; Sharb AA; Levitas D; Assabag Y; Alguayn F; Yakobson A; Rouvinov K; Fuchs L
    Anticancer Drugs; 2022 Jan; 33(1):e738-e740. PubMed ID: 34321417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tislelizumab-Induced Toxic Epidermal Necrolysis-Like Cutaneous Adverse Reaction: Rare Complication of Immune Checkpoint Inhibitor Therapy.
    Yang X; Xu S
    Am J Ther; 2024 Jul-Aug 01; 31(4):e470-e474. PubMed ID: 38976533
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.
    Auquier-Dunant A; Mockenhaupt M; Naldi L; Correia O; Schröder W; Roujeau JC;
    Arch Dermatol; 2002 Aug; 138(8):1019-24. PubMed ID: 12164739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
    Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
    Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicted Value of PD-L1 for Patients With Cervical Cancer Treated With Pembrolizumab.
    Luo PH; Mo DC; Wang HL; Liang XJ; Huang JF
    J Clin Oncol; 2024 May; 42(13):1596. PubMed ID: 38452320
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidermal calprotectin in drug-induced toxic epidermal necrolysis.
    Paquet P; Piérard GE
    J Cutan Pathol; 1999 Jul; 26(6):301-5. PubMed ID: 10472759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
    Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
    R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necroptotic and apoptotic cell death in Toxic Epidermal Necrolysis.
    Stadler PC; Clanner-Engelshofen BM; Helbig D; Satoh T; Reinholz M; French LE
    J Dermatol Sci; 2021 Nov; 104(2):138-141. PubMed ID: 34656387
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypothalamic expression of PD-L1: does it mediate hypothalamitis?
    Iervasi E; Strangio A; Saverino D
    Cell Mol Immunol; 2019 Jun; 16(6):625-626. PubMed ID: 30979971
    [No Abstract]   [Full Text] [Related]  

  • 19. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
    Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP
    Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.